Overview: The Department of Pharmaceuticals has extended the investment schedule for Group C Micro, Small and Medium Enterprises (MSMEs) under the Production-Linked Incentive (PLI) Scheme for Pharmaceuticals. Beneficiaries now have until FY 2026-27 to complete their committed investments. The revised schedule gives them an additional year at each milestone, while the sales-growth conditions and incentive calculation period remain unchanged.
Pharmaceutical Micro, Small and Medium Enterprises (MSMEs), participating in the government’s PLI scheme, have been given more time to complete their investment commitments. A corrigendum issued by the Department of Pharmaceuticals on 30th October, 2026, shifts the investment milestones for Group C MSME beneficiaries by one financial year.
The extension gives smaller manufacturers more time to establish or expand production facilities. However, it does not reduce their approved investment commitments or relax the sales conditions linked to incentive payments. The change applies specifically to Group C MSME beneficiaries, not to all pharmaceutical MSMEs.
PLI Scheme for Pharmaceuticals: Revised Investment Schedule
Under the original operational guidelines issued in June 2021, Group C MSME participants had to complete their committed investments in stages over five years. The corrigendum shifts each milestone forward by one year.
| No. | Investment milestone | Original deadline | Revised deadline |
|---|---|---|---|
| 1 | 20% of committed investment | FY 2021-22 | FY 2022-23 |
| 2 | 40% of committed investment | FY 2022-23 | FY 2023-24 |
| 3 | 60% of committed investment | FY 2023-24 | FY 2024-25 |
| 4 | 80% of committed investment | FY 2024-25 | FY 2025-26 |
| 5 | 100% of committed investment | FY 2025-26 | FY 2026-27 |
The final deadline for completing the committed investment is now FY 2026-27. The change affects the investment timetable; the total investment commitment remains the same.
Sales Conditions and Incentive Period Remain Unchanged
The extension does not remove the sales conditions for receiving incentives. Under the scheme guidelines, Group C MSME participants had to record eligible-product sales of more than ₹50 lakh in FY 2022-23, the first performance year.
From FY 2023-24 onwards, the threshold is calculated at 7% growth over the actual sales of approved eligible products in the preceding financial year. Incentives are linked to incremental sales of eligible products and are subject to the applicable investment and sales criteria.
The performance period for calculating incentives remains FY 2022-23 to FY 2027-28. Beneficiaries seeking incentives for previous performance years under the revised investment schedule will have to submit fresh applications. The Department will examine these applications under the existing scheme guidelines and applicable procedures.
The additional investment time should therefore not be mistaken for an extension of the incentive period or an automatic approval of pending claims.
Pharmaceutical PLI Scheme Has Crossed Its Investment Target
The PLI Scheme for Pharmaceuticals was approved with a financial outlay of ₹15,000 crore to strengthen domestic manufacturing and encourage investment in high-value pharmaceutical products.
According to the Department of Pharmaceuticals, 55 companies, including 20 MSMEs, were selected as beneficiaries. By June 2026, actual investment had reached ₹46,744 crore against the targeted investment of ₹17,275 crore.
Beneficiary companies recorded cumulative sales of ₹4,02,869 crore, including exports of ₹2,57,370 crore. Employment generated under the scheme stood at 1,21,294 jobs. These figures represent the scheme as a whole and are not limited to its MSME participants.
Compliance Requirements as Manufacturing MSMEs Expand
Investment in manufacturing brings responsibilities beyond purchasing machinery and setting up production facilities. As an MSME expands, its promoters need to keep business registrations, financial records, tax filings and statutory obligations in order.
Some of the requirements that growing businesses may need to address include:
- a proprietorship, partnership, LLP or company, depending on its needs. Promoters considering incorporation should assess the appropriate structure and complete the relevant registration formalities.
- Udyam registration: Eligible enterprises should maintain accurate MSME registration details and review their classification when their investment and turnover change.
- GST compliance: Businesses registered under GST must meet their applicable return-filing, tax-payment and reconciliation requirements. E-invoicing and other obligations apply where the prescribed conditions are met.
- MCA compliance: Companies and LLPs must complete the statutory filings applicable to their legal structure, maintain required records and meet relevant reporting deadlines.
- Financial documentation: Properly maintained accounts, financial statements, tax records and statutory documents are useful when a business approaches banks or financial institutions for working capital or expansion finance.
Pharmaceutical manufacturers must also meet the separate regulatory requirements applicable to their products and manufacturing facilities. These may include drug manufacturing licences, quality standards and environmental approvals, depending on the nature of the operation.
Setindiabiz Support
As businesses expand, managing registrations and statutory compliance alongside daily operations place additional demands on promoters. Setindiabiz supports businesses with private limited company and LLP incorporation, Udyam registration, GST registration, return filing, and ongoing MCA compliance.
We also support businesses in organising financial and statutory documentation for lender appraisal. These services address important business and compliance requirements as MSMEs establish operations, expand capacity and seek finance.
The revised PLI schedule gives Group C MSME beneficiaries until FY 2026-27 to complete their committed investments. The sales-growth conditions and incentive performance period, however, remain unchanged. For businesses planning expansion, meeting investment targets is only one part of the process. Maintaining accurate records, completing applicable registrations and meeting statutory deadlines are equally important to running a growing enterprise.
